Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 +2.06%64 EV-to-FCF is 1.94 as of Jul. 18, 2026, which is 80% below its 10-year median of 9.94. GuruFocus rates ROCO:4431 with a GF Score™ of 64/100 and a GF Value™ of NT$37.17 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,733 Industrial Products companies, Mytrex Health Technologies ranks better than 96.25% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mytrex Health Technologies's Enterprise Value is NT$377 Mil.
Mytrex Health Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$195 Mil. Therefore, Mytrex Health Technologies's EV-to-FCF for today is 1.94.
The historical rank and industry rank for Mytrex Health Technologies's EV-to-FCF or its related term are showing as below:
ROCO:4431'
s EV-to-FCF Range Over the Past 10 Years
Min: -43.52 Med: 9.94 Max: 75.86
Current: 1.91
During the past 13 years, the highest EV-to-FCF of Mytrex Health Technologies was 75.86. The lowest was -43.52. And the median was 9.94.
ROCO:4431's EV-to-FCF is ranked better than 96.25% of 1733
companies
in the Industrial Products industry
Industry Median: 24.94
vs ROCO:4431: 1.91
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mytrex Health Technologies (ROCO:4431) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mytrex Health Technologies's PE Ratio (TTM) for today is calculated as:
Mytrex Health Technologies's share price for today is NT$17.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mytrex Health Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.457.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mytrex Health Technologies EV-to-FCF Related Terms
Mytrex Health Technologies EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies EV-to-FCF vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's EV-to-FCF falls into.
Mytrex Health Technologies's current Enterprise Value is NT$377 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mytrex Health Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$195 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mytrex Health Technologies (ROCO:4431) has a EV-to-FCF of 1.94 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mytrex Health Technologies and its competitors. This is 80% below median its historical median of 9.94. According to the industry distribution chart, Mytrex Health Technologies ranks #65 out of 1733 companies in the Industrial Products industry, placing it in the top 3.8%.
Is Mytrex Health Technologies' EV-to-FCF too high?
Mytrex Health Technologies' current EV-to-FCF of 1.94 is 80% below median its 10-year median of 9.94. The Industrial Products industry median EV-to-FCF is 24.94. Mytrex Health Technologies' value of 1.94 is 92.2% below this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #65 out of 1733 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers. Overall, Mytrex Health Technologies has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' EV-to-FCF compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #65 out of 1733 companies for EV-to-FCF. This places Mytrex Health Technologies in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 24.94. Mytrex Health Technologies' value of 1.94 is 92.2% below this benchmark. While the company's 10-year median is 9.94 vs. the industry median of 24.94, Mytrex Health Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Industrial Products company?
The median EV-to-FCF among Industrial Products companies is 24.94, based on 1,733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current EV-to-FCF of 1.94 is 92.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median EV-to-FCF is 24.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current EV-to-FCF is 1.94, which is 80% below median its own 10-year median of 9.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$37.17, compared to a current price of NT$17.35 — trading 53.3% below its estimated fair value. The current EV-to-FCF is 1.94, which is 80% below median its 10-year median of 9.94 and 92.2% below the Industrial Products industry median of 24.94. Mytrex Health Technologies' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current EV-to-FCF is 1.94 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$17.35 is trading 53.3% below its estimated GF Value™ of NT$37.17.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
EV-to-FCF: 1.94 (80% below median its 10-year median of 9.94)
GF Value™: NT$37.17 vs. price of NT$17.35 (53.3% below fair value)
Industry Position: 92.2% below the Industrial Products median (#65 of 1733)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
64GF Score
Get the complete analysis for ROCO:4431
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
